logo-loader
Canntab Therapeutics Ltd

Canntab preparing for a busy summer after partner receives Health Canada License

Canntab Therapeutics (CSE:PILL-OTCQB:CTABF) CFO Richard Goldstein joined Steve Darling from Proactive Investors Vancouver on Skype to discuss their partner FSD Pharma receiving their sale for medical purposes” license by Health Canada.

That designation means Canntab is very close to being in a position to sell its products and generate revenue. The license allows Canntab to produce samples of capsules containing CBD and/or THC, which, once approved by Health Canada, will enable the company to launch production and sales.

Quick facts: Canntab Therapeutics Ltd

Price: $0.63

Market: CSE
Market Cap: $15.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Canntab receives indication of patentability for its release...

Canntab Therapeutics (CSE:PILL.CN-OTCQX: CTABF) Chief Financial Officer Richard Goldstein joined Steve Darling from Proactive Investors Vancouver on Skype with news that the company has received an initial assessment from the Geneva-based International Preliminary Report on Patentability...

4 days, 14 hours ago

2 min read